Business Information
The company's principal activity is to develop, manufacture and market surface modification solutions for the medical device industry. The company operates in three business segments: licensing, manufacturing and research and development. The licensing segment includes all license fees and royalty revenue generated from the transfer of the company's coating technology. The manufacturing segment includes revenues from the sale of chemical reagents, stabilization products and dna slides. Some of the stabilizer products include surmodics, stabilcoat, stabilguard and stabilzyme. The research and development segment includes revenue from development projects for commercial customers and research revenue received from government grants. The major customers of the company include cordis corporation, medtronic inc, amersham plc and abbot laboratories. Licensing accounted for 42% of fiscal 2002 revenues; manufacturing, 31% and research and development, 27%.
|
|
Name |
Title
|
Email
|
| Kendrick Melrose | Chmn. | N/A | | Aron Anderson | VP, Chief Scientific Officer | N/A | | Philip Ankeny | Sr. VP, CFO | N/A | | Arthur Tipton | VP - Surmodics, Pres. - Brookwood Pharmaceuticals | N/A | | Jan Webster | VP - Human Resources | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 69,884 | 20,334 | | 2005 | 62,381 | (8,246) | | 2004 | 49,738 | 7,436
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
